Showing results (1-10 of 35) with videos related to

Sort By:
Pageof 4
JCO Oncology Advances|May 7, 2025
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT AlterationsIbrahim Azar, Husain Yar Khan, Sahar F Bannoura, et al.
JCO Oncology Advances|July 14, 2025
Phase I Trial to Evaluate the Safety of Intralesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaChia-Ching J Wang, Alexander Bang, Sona Chowdhury, et al.
JCO Oncology Advances|February 25, 2026
Risk of Residual Cancer following Immediate Surgery or Nonoperative Management after Malignant Colorectal Polypectomy with High-Risk FeaturesThikhamporn Tawantanakorn, A Begum Bektas, Matthew Hill, et al.
JCO Oncology Advances|May 18, 2026
Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 TrialMoriah Forster, Fengmin Zhao, Sarah Bell, et al.
JCO Oncology Advances|February 7, 2025
Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 TrialQamar J Khan, Colleen Bohnenkamp, Taylor E Monson, et al.
JCO Oncology Advances|December 30, 2024
Challenges and Opportunities in Targeting the Complex Pancreatic Tumor MicroenvironmentJennifer M Finan, Yifei Guo, Shaun M Goodyear, et al.
JCO Oncology Advances|March 26, 2026
Reach, Acceptability, and Effectiveness of Proactive Outreach and Varenicline with Cancer-Focused Counseling for Patients with Cancer: A Pilot Randomized Comparative Effectiveness TrialJesse T Kaye, Thomas M Piasecki, Michael C Fiore, et al.
JCO Oncology Advances|April 2, 2026
Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus-associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311Katherine A Hutcheson, Yael Flamand, Beatrice Manduchi, et al.
JCO Oncology Advances|April 29, 2026
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II StudyEllen M Lavoie Smith, Minji Lee, Mary R Scott, et al.
JCO Oncology Advances|December 8, 2025
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609)Megan Othus, Sandip P Patel, Young Kwan Chae, et al.
Pageof 4